A previous study from this unit showed that only 19% of children withmitral bioprostheses were free from complications after 7 years andprompted us to review the performance of new-generation mechanicalprostheses implanted in the same population group. In a 5-year period(1980-1985), 352 patients 20 years old and younger (mean age 15.3 +/- 4years) with rheumatic valvular disease had 177 mitral, 62 aortic and 113double (mitral + aortic) valve replacements with Medtronic-Hall or St. Judeprostheses. The overall early mortality was 6.3%. All survivors, followedup for a total of 1171 patient-years, received oral anticoagulation. Thelate mortality for mitral, aortic and double valve replacement was 4.1% perpatient-year, 4.3% per patient-year and 8.0% per patient-year, respectively(P less than 0.05), and was valve- related in 46% of the cases. Twenty-ninepatients, all but 2 in the mitral and double valve replacement groups, werereoperated upon (2.5% per patient-year), mainly for infective endocarditis(34%), for prosthetic thrombosis (33%) and for bland periprosthetic leak(31%). The incidence of thrombotic obstruction was 1.1% per patient-year:mitral valve replacement, 1.0% per patient-year; aortic valve replacement0.5% per patient-year; and double valve replacement, 1.7% per patient-year;P less than 0.05) and was fatal in 33% of the cases. Major systemicthromboembolism occurred at the rate of 1.4% per patient- year, similar inthe three groups. The incidence of prosthetic endocarditis was 0.9% perpatient-year.(ABSTRACT TRUNCATED AT 250 WORDS)